The IPO stock has more than tripled in under a year as investors watch its efforts to take on Bristol Myers Squibb (BMY) and Johnson & Johnson (JNJ). The New York-based company has one drug: an oral formulation of the antipsychotic benzamide. It calls the drug LB-102.
Benzamide is approved in…
Extract — continue reading at the source.
Related stories
Canadian whisky on the rocks? Crown Royal is set to avoid Trump’s new ban.
Apple unveils its first folding iPhone
SoFi Dips 3% Despite Reported Kraken Crypto Settlement Tie-Up; Affirm Drops 5%, Robinhood Holds Steady
The New Hunter Biden Meme Coin Is Down 98% Since Launch. Here's What Crypto Investors Need to Know.
Amazon raises £4.25 billion in debut sterling bond sale for AI
Bill Ackman Bets Big on Uber Stock. Should You Follow Him?